|
You are here:
Home: BCU 8| 2002: A chronology of select breast cancer publications
A chronology of select breast cancer publications by Dr Slamon
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL.
Human breast cancer: Correlation of relapse and survival
with amplification of the HER-2/neu oncogene. Science 1987;235(4785):177-82.
Abstract
Bacus SS, Bacus JW, Slamon DJ, Press MF. HER-2/neu oncogene
expression and DNA ploidy analysis in breast cancer. Arch
Pathol Lab Med 1990;114(2):164-9. Abstract
Lupu R, Colomer R, Zugmaier G, Sarup J, Shepard M, Slamon D, Lippman
ME. Direct interaction of a ligand for the erbB2 oncogene
product with the EGF receptor and p185erbB2. Science 1990;249(4976):1552-5.
Abstract
Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly
BM, Ullrich A. Expression of the p185 encoded by HER2 oncogene
in normal and transformed human tissues. Int J Cancer 1990;45(3):457-
61. Abstract
Press MF, Cordon-Cardo C, Slamon DJ. Expression of the
HER-2/neu proto-oncogene in normal human adult and fetal tissues.
Oncogene 1990;5(7):953-62. Abstract
Read LD, Keith D Jr, Slamon DJ, Katzenellenbogen BS. Hormonal
modulation of HER-2/neu protooncogene messenger ribonucleic acid
and p185 protein expression in human breast cancer cell lines. Cancer
Res 1990;50(13):3947-51. Abstract
Slamon DJ. Studies of the HER-2/neu proto-oncogene in
human breast cancer. Cancer Invest 1990;8(2):253. No Abstract
Giovanella BC, Vardeman DM, Williams LJ, Taylor DJ, de Ipolyi
PD, Greeff PJ, Stehlin JS, Ullrich A, Cailleau R, Slamon DJ, et
al. Heterotransplantation of human breast carcinomas in
nude mice. Correlation between successful heterotransplants, poor
prognosis and amplification of the HER- 2/neu oncogene.
Int J Cancer 1991;47(1):66-71. Abstract
Tommasi S, Paradiso A, Mangia A, Barletta A, Simone G, Slamon
DJ, De Lena M. Biological correlation between HER-2/neu
and proliferative activity in human breast cancer. Anticancer
Res 1991;11(4):1395-400. Abstract
Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity
of HER-2/neu antibodies in archival tissue samples: Potential source
of error in immunohistochemical studies of oncogene expression.
Cancer Res 1994;54(10):2771-7. Abstract
Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos
L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ. HER-2
tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent
growth in human breast cancer cells. Oncogene 1995;10(12):2435-46.
Abstract
Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection
and quantitation of HER-2/neu gene amplification in human breast
cancer archival material using fluorescence in situ hybridization.
Oncogene 1996;13(1):63-72. Abstract
Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive
marker of response to breast cancer therapy. Breast Cancer
Res Treat 1998;52(1-3):65-77. Abstract
Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy
D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ. Phase
II study of receptor-enhanced chemosensitivity using recombinant
humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in
patients with HER2/neuoverexpressing metastatic breast cancer refractory
to chemotherapy treatment. J Clin Oncol 1998;16(8):2659-71.
Abstract
Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ. Remission
of human breast cancer xenografts on therapy with humanized monoclonal
antibody to HER-2 receptor and DNA-reactive drugs. Oncogene
1998;17(17):2235-49. Abstract
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher
L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational
study of the efficacy and safety of humanized anti-HER2 monoclonal
antibody in women who have HER2-overexpressing metastatic breast
cancer that has progressed after chemotherapy for metastatic disease.
J Clin Oncol 1999;17(9):2639-48. Abstract
Lopez AM, Pegram MD, Slamon DJ, Landaw EM. A model-based
approach for assessing in vivo combination therapy interactions.
Proc Natl Acad Sci USA 1999;96(23):13023-8. Abstract
Oh JJ, Grosshans DR, Wong SG, Slamon DJ. Identification
of differentially expressed genes associated with HER-2/neu overexpression
in human breast cancer cells. Nucleic Acids Res 1999;27(20):4008-17.
Abstract
Pegram MD, Slamon DJ. Combination therapy with trastuzumab
(Herceptin) and cisplatin for chemoresistant metastatic breast cancer:
Evidence for receptor-enhanced chemosensitivity. Semin
Oncol 1999;26(4 Suppl 12):89-95. Abstract
Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs
D, Baly D, Kabbinavar F, Slamon D. Inhibitory effects of
combinations of HER-2/neu antibody and chemotherapeutic agents used
for treatment of human breast cancers. Oncogene 1999;18(13):2241-51.
Abstract
Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon
DJ. Monoclonal antibody to HER- 2/neureceptor modulates
repair of radiation-induced DNA damage and enhances radiosensitivity
of human breast cancer cells overexpressing this oncogene.
Cancer Res 1999;59(6):1347-55. Abstract
Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon
DJ. Assessment of methods for tissue-based detection of
the HER-2/neu alteration in human breast cancer: A direct comparison
of fluorescence in situ hybridization and immunohistochemistry.
J Clin Oncol 2000;18(21):3651-64. Abstract
Pegram MD, Lopez A, Konecny G, Slamon DJ. Trastuzumab
and chemotherapeutics: Drug interactions and synergies.
Semin Oncol 2000;27(6 Suppl 11):21-5; discussion 92-100. Abstract
Pegram MD, Konecny G, Slamon DJ. The molecular and cellular
biology of HER2/neu gene amplification/overexpression and the clinical
development of herceptin (trastuzumab) therapy for breast cancer.
Cancer Treat Res 2000;103:57-75. No Abstract
Bergman I, Barmada MA, Griffin JA, Slamon DJ. Treatment
of meningeal breast cancer xenografts in the rat using an anti-p185/HER2
antibody. Clin Cancer Res 2001;7(7):2050-6. Abstract
Konecny G, Fritz M, Untch M, Lebeau A, Felber M, Lude S, Beryt
M, Hepp H, Slamon D, Pegram M. HER-2/neu overexpression
and in vitro chemosensitivity to CMF and FEC in primary breast cancer.
Breast Cancer Res Treat 2001;69(1):53-63. Abstract
Konecny G, Untch M, Arboleda J, Wilson C, Kahlert S, Boettcher
B, Felber M, Beryt M, Lude S, Hepp H, Slamon D, Pegram M. Her-2/neu
and urokinase-type plasminogen activator and its inhibitor in breast
cancer. Clin Cancer Res 2001;7(8):2448-57. Abstract
Nabholtz JM, Slamon D. New adjuvant strategies for breast
cancer: Meeting the challenge of integrating chemotherapy and trastuzumab
(Herceptin). Semin Oncol 2001;28(1 Suppl 3):1-12. Abstract
Slamon D, Pegram M. Rationale for trastuzumab (Herceptin)
in adjuvant breast cancer trials. Semin Oncol 2001;28(1
Suppl 3):13-9. Abstract
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde
A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton
L. Use of chemotherapy plus a monoclonal antibody against
HER2 for metastatic breast cancer that overexpresses HER2.
N Engl J Med 2001;344(11):783-92. Abstract
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher
L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart
SJ. First-line Herceptin monotherapy in metastatic breast
cancer. Oncology 2001;61 Suppl 2:37-42. Abstract
Vogel C, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher
L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart
SJ. First-line, single-agent Herceptin® (trastuzumab)
in metastatic breast cancer. A preliminary report. Eur
J Cancer 2001;37 Suppl 1:25-29. Abstract
Osoba D, Slamon DJ, Burchmore M, Murphy M. Effects on
quality of life of combined trastuzumab and chemotherapy in women
with metastatic breast cancer. J Clin Oncol 2002;20(14):3106-13.
Abstract
Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation
of HER-2/neu gene amplification and overexpression: Comparison of
frequently used assay methods in a molecularly characterized cohort
of breast cancer specimens. J Clin Oncol 2002;20(14):3095-105.
Abstract
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher
L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart
SJ, Press M. Efficacy and safety of trastuzumab as a single
agent in first-line treatment of HER2-overexpressing metastatic
breast cancer. J Clin Oncol 2002;20(3):719-26. Abstract
Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch
D, Raju R, Valentine E, Sayre R, Albain K, Cobleigh M, McCullough
C, Fuchs L, Slamon D. Phase III comparative study of trastuzumab
and paclitaxel with and without carboplatin in patients with HER-2/neu
positive advanced breast cancer. Breast Cancer Res Treat
2002;Abstract
35.
|
|
